Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer

被引：0
|
作者：
Gyorffy, B.
Ocana, A.
Herman, P.
Hatzis, C.
Pandiella, A.
Pusztai, L.
机构：
[1] Yale Univ, New Haven, CT 06520 USA
[2] Servicoio Salud Castilla la Mancha, Albacete, Spain
[3] MTA TTK, Budapest, Hungary
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-49
引用
收藏
页数：1
相关论文
共 50 条
  • [31] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [32] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [33] Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/ HER2-negative breast cancer
    Ahn, S. G.
    Cha, Y. J.
    Yoon, C.
    Bae, S. J.
    Kim, J.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Anthracycline-free Neo-adjuvant Treatment for Patients with ER-positive, HER2-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (03) : 248 - 248
  • [35] Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer
    Osako, Tomofumi
    Nishimura, Reiki
    Okumura, Yasuhiro
    Toyozumi, Yasuo
    Arima, Nobuyuki
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (01) : 66 - 71
  • [36] Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
    Kim, Yun Yeong
    Oh, Se Jeong
    Chun, Yong Soon
    Lee, Woon Kee
    Park, Heung Kyu
    PLOS ONE, 2018, 13 (07):
  • [37] Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
    Lee, Dong Neuck
    Li, Yao
    Olsson, Linnea T.
    Hamilton, Alina M.
    Calhoun, Benjamin C.
    Hoadley, Katherine A.
    Marron, J. S.
    Troester, Melissa A.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [38] High tumor grade might be associated with pathologic complete response after neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2020, 25 (02): : 1266 - 1266
  • [39] Multi-gene prognostic signatures and prediction of pathological complete response of ER-Positive HER2-negative breast cancer patients to neo-adjuvant chemotherapy
    Mazo, C.
    Barron, S.
    Mooney, C.
    Gallagher, W. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer-a problem still to be solved
    Schmidt, M.
    Untch, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 754 - 754
12345